We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Labeling of Shire’s Vyvanse Extended to Adolescents
Labeling of Shire’s Vyvanse Extended to Adolescents
November 19, 2010
The FDA has expanded the indication for Shire’s attention deficit hyperactivity disorder (ADHD) drug Vyvanse to include adolescents ages 13 to 17, the company said Nov. 15.